Dandekar Atul 4

4 · Maze Therapeutics, Inc. · Filed Mar 3, 2026

Insider Transaction Report

Form 4

Period: 2026-02-27

Maze Therapeutics, Inc.MAZE

Dandekar Atul

CSBO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-27$10.42/sh+7,500$78,150→ 18,003 total
Sale
Common Stock
[F1][F2]
2026-02-27$45.13/sh−3,739$168,756→ 14,264 total
Sale
Common Stock
[F1][F3]
2026-02-27$45.72/sh−3,761$171,967→ 10,503 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F4]
2026-02-27−7,500→ 59,143 total
Exercise: $10.42Exp: 2031-04-11→ Common Stock (7,500 underlying)
Award
Stock Option (Right to Buy)
[F5]
2026-03-02+38,000→ 38,000 total
Exercise: $45.61Exp: 2036-03-01→ Common Stock (38,000 underlying)
Award
Restricted Stock Units
[F6][F7][F8]
2026-03-02+19,000→ 19,000 total
→ Common Stock (19,000 underlying)

Footnotes (8)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 to $45.54 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
[F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.55 to $46.02 per share, inclusive.
[F4]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
[F5]The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.
[F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
[F7]The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.
[F8]These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-03-03

Documents

1 file

4
form4-03032026_090337.xmlPrimary